Alimentiv Inc., a Canada-based Contract Research Organisation involved in GI-related therapeutics, announce on Friday the addition of new scientific advisors to its scientific advisory board.

The company said that the advisors are internationally recognised experts in designing and conducting clinical research in Inflammatory Bowel Disease. Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.

Dr/prof Remo Panaccione is a professor of Medicine and the director of the Inflammatory Bowel Disease Unit at the University of Calgary, Alberta, Canada. He serves as the dean of MD Admissions and director of the IBD Fellowship Program. He holds the Crohn's Colitis Canada endowed research chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

Dr Panaccione is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and is recognised as a 2020-23 Clarivate Research Scholar for being cited in the top 1 percent of researchers worldwide. He has co-authored over 350 manuscripts, 20 book chapters, and 625 abstracts, including publications in journals such as the New England Journal of Medicine, Lancet, JAMA, Nature, and Annals of Internal Medicine.

Prof Panaccione's primary research interest is designing and implementing clinical trials. He has been the principal investigator on several studies evaluating the efficacy and safety of new therapeutic agents in patients with IBD.

Dr Bruce Sands, MD, MS, is the Dr Burrill B Crohn professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr Sands is widely recognised for his clinical investigations of new therapeutics for inflammatory bowel diseases and has published over 275 original manuscripts. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine, and SEAVUE, published in the Lancet. Dr Bruce Sands serves as a paid consultant for Alimentiv.

'We are committed to the leadership in GI research and proud to work with industry leaders whose research is instrumental in progressing clinical development programs and treatments for patients living with GI-related illnesses,' said Dr Gabriela Radulescu, vice president, Medical Research and Development.